EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EU ADR app to underpin region's regulatory approach to social media
Europe is set to modernize how it conducts some aspects of pharmacovigilance with the launch of a web app in March this year for patients to report adverse drug reactions (ADRs) and a drive to monitor web chatter on the issue. Mick Foy, Group Manager Vigilance Intelligence at the UK’s Medicines and Healthcare products Regulatory Agency, has warned that without progress on the social-media front, manufacturers might shy away from the area to avoid a legal and ethical minefield.